Inhibrx Biosciences Highlights Promising Ozekibart Colorectal Cancer Data
at www.tipranks.com (Tue, 21-Apr 4:49 PM)
Stifel Nicolaus Reaffirms Their Buy Rating on Inhibrx Biosciences Inc (INBX)
at www.tipranks.com (Fri, 17-Apr 8:28 AM)
Inhibrx Cuts R&D Costs Sharply as Two Clinical Trials Push Toward Key 2026 Milestones
Market Chameleon (Fri, 20-Mar 10:59 AM)
